Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Cash & Equivalents: 2015-2025

Historic Cash & Equivalents for Editas Medicine (EDIT) over the last 11 years, with Sep 2025 value amounting to $165.6 million.

  • Editas Medicine's Cash & Equivalents rose 72.85% to $165.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $165.6 million, marking a year-over-year increase of 72.85%. This contributed to the annual value of $131.5 million for FY2024, which is 6.38% up from last year.
  • According to the latest figures from Q3 2025, Editas Medicine's Cash & Equivalents is $165.6 million, which was up 19.57% from $138.5 million recorded in Q2 2025.
  • Over the past 5 years, Editas Medicine's Cash & Equivalents peaked at $354.9 million during Q1 2021, and registered a low of $64.4 million during Q2 2024.
  • For the 3-year period, Editas Medicine's Cash & Equivalents averaged around $123.6 million, with its median value being $129.0 million (2023).
  • As far as peak fluctuations go, Editas Medicine's Cash & Equivalents plummeted by 70.82% in 2024, and later spiked by 114.99% in 2025.
  • Quarterly analysis of 5 years shows Editas Medicine's Cash & Equivalents stood at $203.5 million in 2021, then plummeted by 30.46% to $141.5 million in 2022, then fell by 12.63% to $123.7 million in 2023, then grew by 6.38% to $131.5 million in 2024, then surged by 72.85% to $165.6 million in 2025.
  • Its last three reported values are $165.6 million in Q3 2025, $138.5 million for Q2 2025, and $138.7 million during Q1 2025.